Ian N. Jacobs

Ian N. Jacobs

Auto-generated profile, based on publicly available information

Ian N. Jacobs

Division of Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MAMatthew Aronson
Matthew Aronson
SASoheila Aliakbarighavimi
Soheila Aliakbarighavimi
PGPaul Gehret
Paul Gehret
IJIan N. Jacobs
Ian N. Jacobs
RGRiccardo Gottardi
Riccardo Gottardi

24 June 2023 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
IJIan N. Jacobs
Ian N. Jacobs
TGTeresa Giordano
Teresa Giordano
ASAshley Soaper
Ashley Soaper
TDTaseer Feroze Din
Taseer Feroze Din
WFWalter Faig
Walter Faig
JPJoseph Piccione
Joseph Piccione

23 May 2021 in Seminars in Pediatric Surgery
Verified
Journal Article
Closed access
IJIan N. Jacobs
Ian N. Jacobs
KJKris R. Jatana
Kris R. Jatana

5 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CKChelsea Kotch
Chelsea Kotch
KWKristina Wagner
Kristina Wagner
JBJ. Harris Broad
J. Harris Broad
EDEva Dombi
Eva Dombi
JMJane E. Minturn
Jane E. Minturn
JBJean Belasco
Jean Belasco
Limited therapies exist for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN). For this reason, the activity of vinblastine (VBL) and methotrexate (MTX) was evaluated in children and young adults with NF1 and PN. Patients ≤ 25 years of age with progressive and/or inoperable NF1-PN received VBL 6 mg/m2 and MTX 30 mg/m2 weekly for 26 weeks, followed by every 2 weeks for 26 weeks. Objective response rate was the primary endpoint. Of 25 participants enrolled, 23 were evaluable. The median age of participants was 6.6 years (range 0.3–20.7). The most frequent toxicities were neutropenia and elevation of transaminases. On two-dimensional (2D) imaging, 20 participants (87%) had stable tumor, with a median time to progression of 41.5 months (95% confidence interval 16.9, 64.9). Two of eight participants (25%) with airway involvement demonstrated functional improvements including decreased positive pressure requirements and apnea-hypopnea index. A post hoc three-dimensional (3D) analysis of PN volumes was completed on 15 participants with amenable imaging; 7 participants (46%) had progressive disease on or by the end of therapy. VBL/MTX was well-tolerated but did not result in objective volumetric response. Furthermore, 3D volumetric analysis highlighted the lack of sensitivity of 2D imaging for PN response evaluation.

1 January 2007
Verified
Book Chapter
Closed access
KZKaren B. Zur
Karen B. Zur
IJIan N. Jacobs
Ian N. Jacobs

9 June 2005
Verified
Book Chapter
Closed access
IJIan Jacobs
Ian Jacobs
David A LowDavid A Low
David A Low
TCTimothy Crombleholme
Timothy Crombleholme